[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100650337":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":30,"locations":36,"responsibleParty":54,"collaborators":25,"id":56,"slug":57,"hasResults":58,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":62,"eligibilityCriteria":63,"healthyVolunteers":58,"sex":64,"minAge":65,"maxAge":25,"enrollmentInfo":66,"targetDuration":25,"studyType":69,"phases":70,"briefSummary":72,"conditions":73,"keywords":76,"overallStatus":84,"whyStopped":25,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":89,"completionDateStruct":90,"leadSponsor":92,"locationsCount":93},{"fullName":5,"class":6},"Clínica Dávila","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Continuous Desflurane","EXPERIMENTAL","Participants receive desflurane as the inhalational anesthetic throughout the entire elective laparoscopic bariatric surgery according to the study protocol.",[13],"Drug: Desflurane",{"label":15,"type":10,"description":16,"interventionNames":17},"Sevoflurane-Desflurane Swap","Participants receive sevoflurane during most of the procedure and are switched to desflurane 30 minutes before the end of surgery according to the study protocol.",[18],"Drug: Sevoflurane-Desflurane",[20,26],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Desflurane","Desflurane administered as the inhalational anesthetic throughout the surgical procedure.",[9],null,{"type":21,"name":27,"description":28,"armGroupLabels":29,"otherNames":25},"Sevoflurane-Desflurane","Sevoflurane administered during the initial phase of surgery followed by desflurane beginning 30 minutes before surgical closure.",[15],[31],{"name":32,"role":33,"phone":34,"phoneExt":25,"email":35},"Magdalena Estefo, MD","CONTACT","+56 9 7986 5505","magdalenaestefo@gmail.com",[37],{"facility":5,"status":25,"city":38,"state":39,"zip":40,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"Santiago","Santiago Metropolitan","8431657","Chile","CL",{"type":44,"coordinates":45},"Point",[46,47],-70.64827,-33.45694,{"lat":47,"lon":46},[50],{"name":51,"role":33,"phone":52,"phoneExt":25,"email":53},"Alejandra Alejandra Rivera, MsC Epidemiology","930363776","alejandra.rivera@davila.cl",{"type":55,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100650337","phase-4-swap-anesthetic-versus-continuous-desflurane-in-adults-undergoing-bariatric-surgery-100650337",false,"NCT07748247","Swap Anesthetic Versus Continuous Desflurane in Adults Undergoing Bariatric Surgery","Desflurane Versus Sevoflurane-Desflurane Swap in Adults Undergoing Bariatric Surgery: A Randomized Non-Inferiority Trial on Extubation Time","SWAP","Inclusion Criteria:\n\n* Age 18 years or older.\n* Scheduled for elective laparoscopic gastric bypass surgery.\n* Body mass index between 30 and 50 kg\u002Fm².\n* American Society of Anesthesiologists physical status II or III.\n* Able and willing to provide written informed consent.\n\nExclusion Criteria:\n\n* Surgical procedure lasting less than 2 hours.\n* Body mass index greater than 50 kg\u002Fm².\n* Significant cardiac disease.\n* Moderate or severe obstructive respiratory disease, including uncontrolled asthma or chronic obstructive pulmonary disease.\n* Pregnancy or breastfeeding.\n* Known allergy or contraindication to medications used during the intraoperative period.\n* Personal or family history of malignant hyperthermia.\n* Active illicit drug use or substance dependence.\n* Advanced chronic kidney disease, defined as an estimated glomerular filtration rate below 60 mL\u002Fmin.\n* Myasthenia gravis or another neuromuscular junction disorder.\n* Severe cognitive or psychiatric disorder.\n* Refusal to participate or withdrawal of informed consent at any time.","ALL","18 Years",{"count":67,"type":68},82,"ESTIMATED","INTERVENTIONAL",[71],"PHASE4","This randomized, parallel-group, non-inferiority clinical trial aims to evaluate whether an anesthetic swap strategy consisting of sevoflurane followed by desflurane 30 minutes before the end of surgery is non-inferior to continuous desflurane anesthesia with respect to extubation time in adults undergoing elective laparoscopic bariatric surgery. Secondary outcomes include time to achieve a Patient State Index (PSi) greater than 80, time to achieve an Aldrete score of at least 8, incidence of postoperative nausea and vomiting, post-anesthesia care unit length of stay, and desflurane-related costs.",[74,75],"Obesity","Bariatric Surgery",[22,77,78,75,79,74,80,81,82,83],"Sevoflurane","General Anesthesia","Extubation Time","Laparoscopic Gastric Bypass","Randomized Trial","Non-Inferiority Trial","Patient State Index","NOT_YET_RECRUITING","2026-08-03",{"date":87,"type":88},"2026-08-05","ACTUAL",{"date":85,"type":68},{"date":91,"type":68},"2027-04",{"name":5,"class":6},1]